Nutriband (NTRB) announced that the United States Food and Drug Administration, FDA, has granted a Type C Meeting for its lead product, AVERSA FENTANYL. The purpose of the meeting is to specifically provide feedback on the Chemistry, Manufacturing, and Controls, CMC, plans for the product from submission of an Investigational New Drug Application, IND, through approval of a 505(b)(2) New Drug Application, NDA, and subsequent commercialization. The meeting is scheduled as a virtual face-to-face meeting to be held on September 18, 2025 with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine, DAAP, in the Office of Neuroscience, ON, Center for Drug Evaluation and Research, CDER.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRB:
- Nutriband Completes Stock Dividend of Preferred Shares
- Nutriband confirms record, pay date for 25% preferred stock dividend
- Nutriband Approves New Series A Preferred Stock
- Nutriband board approves 25% Preferred Stock dividend
- Nutriband added to Russell Microcap, Russell Microcap Growth, Russell 3000E